For the quarter ending 2026-03-31, PRAX had $179,004K increase in cash & cash equivalents over the period. -$86,214K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | - | 0 | 0 | - |
| Program-specific expenses-Ulixacaltamide | 19,103 | 9,665 | 11,644 | - |
| Program-specific expenses-Vormatrigine | 20,494 | 21,470 | 20,899 | - |
| Program-specific expenses-Relutrigine | 12,854 | 15,100 | 14,965 | - |
| Program-specific expenses-Elsunersen | 3,197 | 2,536 | 2,219 | - |
| Program-specific expenses-Other Early State Assets | 3,242 | 2,355 | 3,142 | - |
| Personnel-related expenses | 17,730 | 27,660 | 12,116 | - |
| Stock-based compensation expense | 17,112 | 9,938 | 7,447 | - |
| Depreciation expense | 39 | 28 | 19 | - |
| Other segment expenses | 12,089 | 8,292 | 5,908 | - |
| Interest income | - | - | 4,425 | - |
| Other income, net | 13,299 | 22,930 | - | - |
| Net loss | -92,561 | -88,911 | -73,934 | -140,423 |
| Depreciation expense | 39 | 28 | 19 | 93 |
| Stock-based compensation expense | 17,112 | 9,938 | 7,447 | 16,556 |
| Non-cash operating lease expense | 197 | 271 | 263 | 506 |
| Amortization of premiums and discounts on marketable securities, net | 655 | 671 | 705 | 2,216 |
| Operating lease liabilities | - | - | -319 | -614 |
| Non-cash collaboration and license agreement expense | - | 0 | 0 | 0 |
| Other non-cash adjustments | - | 7 | - | - |
| Prepaid expenses and other current assets | -672 | 4,894 | 1,383 | -6,917 |
| Deferred revenue | - | 0 | 0 | 0 |
| Accounts payable | 6,530 | -6,194 | 1,987 | 16,304 |
| Accrued expenses | -17,385 | 14,428 | 1,578 | -4,806 |
| Operating lease liabilities | -101 | -1,259 | - | - |
| Other | 0 | 13 | -10 | -3 |
| Net cash used in operating activities | -86,152 | -76,325 | -65,057 | -107,686 |
| Purchases of property and equipment | 62 | 0 | 0 | 56 |
| Purchases of marketable securities | 486,782 | 390,275 | 75,133 | 158,404 |
| Maturities of marketable securities | 142,569 | 61,884 | 125,546 | 125,290 |
| Net cash used in investing activities | -344,275 | -328,391 | 50,413 | -33,170 |
| Proceeds from exercise of options and employee stock purchase plan purchases | - | 11,612 | 808 | 854 |
| Proceeds from stock offerings, net of issuance costs-License And Collaboration Agreement | - | 0 | 0 | 0 |
| Proceeds from stock offerings, net of issuance costs-Follow On Offering | 621,235 | 567,115 | 0 | 0 |
| Proceeds from stock offerings, net of issuance costs-At The Market Offering | 0 | 34,610 | 6,000 | 83,263 |
| Payments of tax withholdings related to vesting of restricted stock units | 12,923 | 819 | 52 | 1,218 |
| Proceeds from exercise of stock options | 1,119 | - | - | - |
| Net cash provided by financing activities | 609,431 | 612,518 | 6,756 | 82,899 |
| Increase (decrease) in cash, cash equivalents and restricted cash | 179,004 | 207,802 | -7,888 | -57,957 |
| Cash, cash equivalents and restricted cash, beginning of period | 149,943 | - | 215,788 | - |
| Cash, cash equivalents and restricted cash, end of period | 536,749 | - | 149,943 | - |
Praxis Precision Medicines, Inc. (PRAX)
Praxis Precision Medicines, Inc. (PRAX)